Koshi Matsui
Overview
Explore the profile of Koshi Matsui including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagasawa S, Matsui K, Araki M, Kanaya E, Takagi K, Muranushi R, et al.
Surg Case Rep
. 2025 Feb;
11(1).
PMID: 40008370
Introduction: Pleomorphic adenoma is a benign tumor that frequently occurs in the salivary glands; however, it occurs in the breast rarely. There have been few reports of breast cancer complicated...
2.
Araki M, Matsui K, Takagi K, Kanaya E, Sekine S, Nagasawa S, et al.
Surg Case Rep
. 2023 Aug;
9(1):137.
PMID: 37530896
Background: Squamous cell carcinoma (SCC) of the breast is a rare form of breast cancer, accounting for approximately 0.1% of all breast cancers. It is known for its rapid tumor...
3.
Akashi T, Okumura T, Terabayashi K, Yoshino Y, Tanaka H, Yamazaki T, et al.
Oncol Lett
. 2023 Jun;
26(1):320.
PMID: 37332339
Despite recent advances in multidisciplinary treatments of esophageal squamous cell carcinoma (ESCC), patients frequently suffer from distant metastasis after surgery. For numerous types of cancer, circulating tumor cells (CTCs) are...
4.
Matsui K, Earashi M, Yoshikawa A, Fukushima W, Nozaki Z, Oyama K, et al.
Mol Clin Oncol
. 2023 Feb;
18(2):12.
PMID: 36761387
Bevacizumab and eribulin are novel agents for the treatment of HER2-negative metastatic breast cancer (MBC); however, the choice between bevacizumab and eribulin for MBC can be difficult. The present study...
5.
Fukuda T, Baba H, Okumura T, Kanda M, Akashi T, Tanaka H, et al.
Anticancer Res
. 2022 Dec;
43(1):35-43.
PMID: 36585184
Background/aim: MicroRNAs (miRNAs) are abnormally expressed and involved in the pathogenesis of various carcinomas. The present study aimed to identify novel miRNA genes associated with the pathogenesis and prognosis of...
6.
Sakai A, Okumura T, Miwa T, Watanabe T, Numata Y, Araki M, et al.
J Surg Case Rep
. 2022 Jan;
2021(12):rjab574.
PMID: 34987762
With recent advances in the treatment of esophageal cancer and long-term survival after esophagectomy, the number of gastric tube cancer (GTC) has been increasing. Total gastric tube resection with lymph...
7.
Satake T, Muto M, Okamoto M, Onoda S, Matsui K, Narui K, et al.
Microsurgery
. 2022 Jan;
42(5):441-450.
PMID: 34985152
Background: In some breast cancer patients with a contralateral unaffected hypertrophic and ptotic breast, autologous small-breast reconstruction with contralateral breast reduction is a good option. The current study is aimed...
8.
Okumura T, Miwa T, Watanabe T, Akashi T, Nomoto K, Kimura N, et al.
Int J Surg Case Rep
. 2021 Aug;
85:106243.
PMID: 34388895
Introduction And Importance: Mediastinal cystic lesions, such as paratracheal air cyst (PTAC) and bronchogenic cyst (BC), are rare anomaly usually found incidentally in thoracic imaging. Special attention is needed in...
9.
Matsui K, Satake T, Araki M, Kanaya E, Igarashi T, Okamoto M, et al.
J Surg Case Rep
. 2021 Jul;
2021(7):rjab241.
PMID: 34262688
The deep inferior epigastric perforator (DIEP) flap is widely recognized as safe for use as a first-choice option in autologous tissue breast reconstruction; however, DIEP is often not performed for...
10.
Kimura N, Yamada S, Takami H, Murotani K, Yoshioka I, Shibuya K, et al.
Cancers (Basel)
. 2020 Dec;
13(1).
PMID: 33374369
The objective of this study was to investigate the optimal neoadjuvant therapy (NAT) for borderline resectable pancreatic cancer invading the portal vein (BR-PV) or abutting major arteries (BR-A). We retrospectively...